Skip to main content
Clinical Trials/NCT05037617
NCT05037617
Completed
N/A

The REDUCED-I Pilot Trial: REDucing the Utilization of CEsarean Sections With Induction

University of Calgary1 site in 1 country205 target enrollmentOctober 25, 2021

Overview

Phase
N/A
Intervention
Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
Conditions
Induced; Birth
Sponsor
University of Calgary
Enrollment
205
Locations
1
Primary Endpoint
Rate of Cesarean section in labor
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

This pilot project is a randomized controlled trial where induced patients receive an intervention of oxytocin discontinuation once in the active stage of labor (≥6 cm dilation). The intent is to reduce uterine hyperstimulation and fetal distress, therefore, lowering cesarean sections (CS) in first time mothers at term (≥ 37 weeks), with a cephalic presenting singleton fetus, without increasing maternal or neonatal morbidity. If REDUCE-I pilot trial suggests a safe reduction in CS rates and patient satisfaction, application for a multi-centre randomized controlled trial would follow.

Detailed Description

This pilot project is a randomized controlled trial of a proposed intervention to modify management of labor inductions once in the active first stage of labor. The intervention will take place at Foothills Medical Centre (FMC). Randomization will be computer generated, participants will be stratified by need for cervical ripening and randomization will be blocked. Participants will be primiparous women 18 years old or older, at term (≥ 37 weeks) with a cephalic presenting singelton fetus undergoing induction of labor with oxytocin. Once patients are in the active first stage of labor, study medication will be initiated (identical vials of oxytocin or saline prepared by the Alberta Health Services Research Pharmacy). Treatment period will continue until delivery. If the frequency of contractions are reduced to less than 2 in 10 minutes or there has been no change in dilation for 4 hours, then oxytocin can be restarted. Royal Alexandra Hospital in Edmonton will be used as a contemporaneous non-intervention control site.

Registry
clinicaltrials.gov
Start Date
October 25, 2021
End Date
February 15, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Stephen Wood

Professor

University of Calgary

Eligibility Criteria

Inclusion Criteria

  • pregnant women undergoing induction of labor with oxytocin.
  • Primiparous
  • 18 years old or older
  • at term (≥37 weeks)
  • cephalic presenting
  • singleton fetus

Exclusion Criteria

  • Multiple pregnancies
  • known fetal congenital or chromosomal anomalies

Arms & Interventions

Intervention site (Foothills Medical Centre): Continuation of Oxytocin

Participants in this arm will receive a blinded vial of oxytocin once a patient is found to be \>= 6 cm dilated.

Intervention: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).

Intervention site (Foothills Medical Centre): Discontinuation of oxytocin

Participants in this arm will receive a blinded vial of saline solution once a patient is found to be \>= 6 cm dilated.

Intervention: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).

Outcomes

Primary Outcomes

Rate of Cesarean section in labor

Time Frame: At Delivery

Rate of Cesarean section in labor

Occurrence of Uterine Hyperstimulation

Time Frame: During labour, after >=6 cm dilation

Occurrence of \>5 contractions in 10 minutes

Proportion of screened subjects who agree to enroll in the trial

Time Frame: During screening of potential participants

Proportion of screened subjects who agree to enroll in the trial

Secondary Outcomes

  • Rate of postpartum hemorrhage(At delivery)
  • Rate of postpartum uterine artery/pelvic artery embolization(Within 28 days of delivery)
  • Rate of postpartum hysterectomy(Within 28 days of delivery)
  • Rate of postpartum maternal intensive care unit (ICU) admission(At delivery)
  • Rate of perinatal death(At delivery)
  • Rate of moderate or severe asphyxia (Sarnat) or meets criteria for therapeutic cooling(At delivery)
  • Rate of neonatal asphyxia(At delivery)
  • Rate of neonatal sepsis or suspected sepsis(At delivery)
  • Rate of blood transfusion(At delivery)

Study Sites (1)

Loading locations...

Similar Trials